| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- GSK-25
-
- $39.00
-
2026-07-14
- CAS:874119-56-9
- Purity: 99.29%
- Supply Ability: 10g
|
| Product Name: | GSK-25 | | Synonyms: | 4-(4-Chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide;GSK-25;5-PyriMidinecarboxaMide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-Methyl-;4-(4-Chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4;GSK25;GSK 25;4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-1-(6-fluoro-1H-indazol-5-yl)-6-methyl-4H-pyrimidine-5-carboxamide;Rho-associated kinase,ROK,ROCK,Rho-associated protein kinase,S6K,bioavailable,Ribosomal S6 Kinase (RSK),Rho-kinase,Inhibitor,p70S6K,selective,pressure,P450,inhibit,GSK-25,GSK 25,blood,orally;4-(4-Chloro-2-fluorophenyl)-2-(2-chloro-4-pyridyl)-N-(6-fluoro-5-indazolyl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide | | CAS: | 874119-56-9 | | MF: | C24H16Cl2F2N6O | | MW: | 513.33 | | EINECS: | | | Product Categories: | | | Mol File: | 874119-56-9.mol |  |
| | GSK-25 Chemical Properties |
| Boiling point | 751.7±60.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (194.81 mM) | | form | Solid | | pka | 11.61±0.40(Predicted) | | color | Light yellow to yellow |
| | GSK-25 Usage And Synthesis |
| Uses | GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively)[1]. | | in vivo | GSK-25 (Rat aorta IC50=256 nM) is profiled in a spontaneously hypertensive rat (SHR) model of hypertension. At 30 mg/kg (p.o.), GSK-25 induces a 25 mmHg (t=3 hours) drop in blood pressure[1].
GSK-25 has promising oral bioavailability (49% in male Sprague-Dawley rats and 19% in monkey), good half-life (1.8 hours in rat and 2.2 hours in monkey)[1]. | | IC 50 | ROCK1: 7 nM (IC50); RSK1: 398 nM (IC50); p70S6K: 1000 nM (IC50) | | References | [1] Sehon CA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008 Nov 13;51(21):6631-4. DOI:10.1021/jm8005096 |
| | GSK-25 Preparation Products And Raw materials |
|